1. Additional file 1 of Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial
- Author
-
Haeberle, Helene A., Calov, Stefanie, Martus, Peter, Serna-Higuita, Lina Maria, Koeppen, Michael, Goll, Almuth, Bernard, Alice, Zarbock, Alexander, Meersch, Melanie, Weiss, Raphael, Mehrländer, Martin, Marx, Gernot, Putensen, Christian, Bakchoul, Tamam, Magunia, Harry, Nieswandt, Bernhard, Mirakaj, Valbona, and Rosenberger, Peter
- Abstract
Additional file 1: Table S1. Organ Specific Baseline Characteristics and Ventilation Parameters. Table S2. Primary Endpoint, COVID 19 patients only. Table S3. Primary Endpoint (PaO2/FiO2 ratio Day 5), adjusted by Ventilatory ratio and therapy. Table S4. Primary Endpoint in age strata. Figure S1. A) PaO2/FiO2 (min) during follow up with Iloprost vs placebo, B) PaO2/FiO2 (max) during follow up with Iloprost vs placebo. C) PaO2/FiO2 before and during therapy with Iloprost vs placebo total cohort, D) Covid-19 Positive, E) Covid-19 negative. Figure S2. Ventilatory ratio (VR) in the Placebo and treatment arm. Figure S3. A) Ninety-day mortality rates in COVID-19-negative and COVID-19-positive patients and B) 90-day mortality rates in COVID-19-negative patients in the Iloprost-treated group compared with control (NaCl)-treated patients. Figure S4. Subgroup analysis.
- Published
- 2023
- Full Text
- View/download PDF